Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1371/journal.ppat.1009243 http://scihub22266oqcxt.onion/10.1371/journal.ppat.1009243 33524041!7877736!33524041     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=33524041&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\33524041.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       PLoS+Pathog 2021 ; 17 (2): e1009243 Nephropedia Template TP {{tp|p=33524041|t=2021. Metabolomic/lipidomic profiling of COVID-19 and individual response to tocilizumab |pdf=|usr=}}{{33524041}} gab.com Text Metabolomic/lipidomic profiling of COVID-19 and individual response to tocilizumab JO: PLoS Pathog http://www.kidney.de/pget.php?&tw=1&pmid=33524041 #FOAvip The current pandemic emergence of novel coronavirus disease (COVID-19) poses a relevant threat to global health. SARS-CoV-2 infection is characterized by a wide range of clinical manifestations, ranging from absence of symptoms to severe forms that need intensive care treatment. Here, plasma-EDTA samples of 30 patients compared with age- and sex-matched controls were analyzed via untargeted nuclear magnetic resonance (NMR)-based metabolomics and lipidomics. With the same approach, the effect of tocilizumab administration was evaluated in a subset of patients. Despite the heterogeneity of the clinical symptoms, COVID-19 patients are characterized by common plasma metabolomic and lipidomic signatures (91.7% and 87.5% accuracy, respectively, when compared to controls). Tocilizumab treatment resulted in at least partial reversion of the metabolic alterations due to SARS-CoV-2 infection. In conclusion, NMR-based metabolomic and lipidomic profiling provides novel insights into the pathophysiological mechanism of human response to SARS-CoV-2 infection and to monitor treatment outcomes. Twit Text FOAVip Metabolomic/lipidomic profiling of COVID-19 and individual response to tocilizumab ????PLoS Pathog http://www.kidney.de/pget.php?&tw=1&pmid=33524041 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33524041 #FOAvip English Wikipedia <ref>{{Cite pmid|33524041}}</ref> Metabolomic/lipidomic profiling of COVID-19 and individual response to tocilizumab #MMPMID33524041 Meoni G; Ghini V; Maggi L; Vignoli A; Mazzoni A; Salvati L; Capone M; Vanni A; Tenori L; Fontanari P; Lavorini F; Peris A; Bartoloni A; Liotta F; Cosmi L; Luchinat C; Annunziato F; Turano P PLoS Pathog 2021[Feb]; 17 (2): e1009243 PMID33524041show ga The current pandemic emergence of novel coronavirus disease (COVID-19) poses a relevant threat to global health. SARS-CoV-2 infection is characterized by a wide range of clinical manifestations, ranging from absence of symptoms to severe forms that need intensive care treatment. Here, plasma-EDTA samples of 30 patients compared with age- and sex-matched controls were analyzed via untargeted nuclear magnetic resonance (NMR)-based metabolomics and lipidomics. With the same approach, the effect of tocilizumab administration was evaluated in a subset of patients. Despite the heterogeneity of the clinical symptoms, COVID-19 patients are characterized by common plasma metabolomic and lipidomic signatures (91.7% and 87.5% accuracy, respectively, when compared to controls). Tocilizumab treatment resulted in at least partial reversion of the metabolic alterations due to SARS-CoV-2 infection. In conclusion, NMR-based metabolomic and lipidomic profiling provides novel insights into the pathophysiological mechanism of human response to SARS-CoV-2 infection and to monitor treatment outcomes. |*COVID-19 Drug Treatment[MESH] |*Lipidomics[MESH] |Antibodies, Monoclonal, Humanized/*administration & dosage[MESH] |COVID-19/blood/epidemiology[MESH] |Female[MESH] |Humans[MESH] |Lipids/*blood[MESH] |Male[MESH] |Nuclear Magnetic Resonance, Biomolecular[MESH]Metabolomic/lipidomic profiling of COVID-19 and individual response to(epmc).pdf DeepDyve Pubget Overpricing